Migraine and tension-type headache (TTH)
are common primary disorders that carry significant morbidity and
socioeconomic effect. In this article, we will review the epidemiology,
presentation, and diagnosis of these disorders. First-line acute
treatment for migraine consists of analgesics, triptans, and
antiemetics, while nonsteroidal anti-inflammatory drugs are the mainstay
treatment for TTH. Patients with frequent or chronic headaches warrant
prophylactic therapy. For migraine, various classes of preventives can
be used (β-blockers, tricyclics, antiepileptics, botulinum toxin), with
the choice of therapy tailored to the patient's risk factors and
symptoms. For TTH, tricyclics have the most evidence as prophylactic
therapy. A new class of medication, monoclonal antibodies to calcitonin
gene receptor peptide or its receptor, became available in 2018, and is
the first class of medication specifically designed to treat migraine.
In addition to pharmacotherapy, we will also review nonpharmacologic
interventions as well as neuromodulation for migraine.
No comments:
Post a Comment